Vaginal News and Research

RSS

Banana lectin discovery may lead to potential new treatments for preventing sexual transmission of HIV

A potent new inhibitor of HIV, derived from bananas, may open the door to new treatments to prevent sexual transmission of HIV, according to a University of Michigan Medical School study published this week.

16 Mar 2010

Amnesty International: Office of Maternal Health need to be established to reduce maternal deaths nationwide

Amnesty International called on President Obama today to quickly establish an Office of Maternal Health to lead government action to reduce soaring pregnancy-related complications and maternal deaths nationwide. The human rights organization said the government must take immediate steps to stop the loss of two to three women every day and reduce the risk of complications that now affect one-third of all pregnant women -- 1.7 million women a year.

12 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

NIH panel recommends delivery options for women: VBAC or cesarean

An independent panel convened this week by the National Institutes of Health confronted a troubling fact that pregnant women currently have limited access to clinicians and facilities able and willing to offer a trial of labor after previous cesarean delivery because of so-called VBAC bans.

11 Mar 2010

'Had Sex': Different perceptions

When people say they "had sex," what transpired is anyone's guess. A new study from the Kinsey Institute at Indiana University found that no uniform consensus existed when a representative sample of 18- to 96-year-olds was asked what the term meant to them.

5 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Aurora Health Care establishes new clinic for treating chronic vulvar pain

It is a sensitive subject for many women. The issue is chronic vulvar pain, and it impacts one out of six women at some point in their lives. However, most women are unaware of their treatment options.

3 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

Over 16% of pregnant women diagnosed with gestational diabetes

Two to three times more pregnant women may soon be diagnosed and treated for gestational diabetes, based on new measurements for determining risky blood sugar levels for the mother and her unborn baby, according to a study that was coordinated by investigators at Northwestern University Feinberg School of Medicine.

26 Feb 2010

Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

23 Feb 2010

News outlets examine use of ART, microbicide development presented at conference

News outlets continue to report on the science discussed at the Conference on Retroviruses and Opportunistic Infections (CROI), which ended Friday in San Francisco.

23 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Changes in vaginal pH make women more susceptible to infections

Changes in vaginal pH as a result of common “pH triggers” make women more susceptible to infections such as bacterial vaginosis (BV). Understanding how the vaginal environment responds to pH fluctuation helps health professionals prevent and treat these conditions.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Researcher receives $2.4M grant from NIH to study preeclampsia and diabetes in pregnant women

The link between obesity and high-risk pregnancies caused by preeclampsia and diabetes will be the focus of a $2.4 million National Institutes of Health research grant received by Sean Blackwell, M.D., associate professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at The University of Texas Medical School at Houston.

15 Feb 2010

HIV transmission among male partners: CFAR scientists discover origin of strains

A team of scientists, led by a virologist from the University of California, San Diego's Center for AID Research (CFAR), has discovered the origin of strains of human immunodeficiency virus (HIV) among men who have sex with men. The study, which may be important in developing prevention strategies for HIV, will appear in Science Translational Medicine on February 10, 2010.

12 Feb 2010

Also in Global Health News: China's health care system; Breastfeeding practices in Pakistan; HIV transmission in MSM; Abu Dhabi joins malaria fight

The Los Angeles Times examines China's transition to "Western-style privatized medicine" through the government's "$124-billion overhaul, chiefly to improve service in rural areas." The article details the efforts of a woman from Inner Mongolia to get care in Beijing for her ailing father and looks at climbing health care costs and the growing "black market for medical care" (Pierson, 2/11).